KAPA — Kairos Pharma, LTD.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1962011 ·
Last close
$0.31
Market Cap
$6.55M
52W High
$0.60
52W Low
$0.27
ADV30
4,210,517
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,690,000 | -1,654,000 | 5,744,000 | 3,675,000 | 431,000 |
| Dec 2025 | 0 | — | -1,415,000 | -1,365,000 | 6,540,000 | 4,491,000 | 199,000 |
| Sep 2025 | 0 | — | -1,435,000 | -1,398,000 | 8,066,000 | 5,575,000 | 402,000 |
| Jun 2025 | 0 | — | -1,456,000 | -1,422,000 | 6,673,000 | 3,034,000 | 676,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,763,000
Investing CF
—
Financing CF
$3,822,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.31
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-15,916,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-5,875,000
Pretax Income TTM
$-5,839,000
Interest Exp TTM
$0
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,572,000 | -5,447,000 | 6,540,000 | 199,000 | — | -3,441,000 |
| Dec 2024 | 0 | -2,343,000 | -2,603,000 | 5,768,000 | 992,000 | — | -3,955,000 |
| Dec 2023 | 0 | -1,714,000 | -1,812,000 | 965,000 | 3,043,000 | — | 81,000 |
| Dec 2022 | 0 | -571,000 | -1,050,000 | 1,036,000 | 2,215,000 | — | -353,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADXN | Addex Therapeutics Ltd. | $6.58M | $5.20 | — |
| IMNN | Imunon, Inc. | $6.68M | $1.59 | — |
| CANF | Can-Fite BioPharma Ltd. | $6.75M | $3.15 | — |
| PULM | Pulmatrix, Inc. | $6.35M | $1.74 | — |
| ENVB | Enveric Biosciences, Inc. | $6.32M | $1.57 | — |
News headlines (Yahoo Finance, 1h cache)
Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health
2026-07-22 21:10 · Yahoo
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
2026-07-22 12:35 · Yahoo
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
2026-07-15 12:39 · Yahoo
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
2026-07-15 12:30 · Yahoo
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy
2026-07-02 16:00 · Yahoo
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
2026-05-13 09:30 · Yahoo
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
2026-03-03 10:54 · Yahoo
Kairos Pharma reports positive data from Phase II prostate cancer treatment trial
2025-09-19 11:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.